Showing results (121-130 of 201) with videos related to

Sort By:
Pageof 21
Blood|October 26, 2016
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemiaSarah K Tasian, David T Teachey, Yong Li, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 1, 2020
Human Adenovirus 7-Associated Hemophagocytic Lymphohistiocytosis-like Illness: Clinical and Virological Characteristics in a Cluster of Five Pediatric CasesWilliam R Otto, Edward M Behrens, David T Teachey, et al.
Leukemia|April 12, 2022
JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemiaKimberly Bodaar, Natsuko Yamagata, Anais Barthe, et al.
The Journal of Clinical Investigation|November 6, 2019
Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytesLauren K Meyer, Benjamin J Huang, Cristina Delgado-Martin, et al.
Blood|March 18, 2025
STAT1-mediated interferon signatures are associated with preclinical JAK inhibitor sensitivity in T-ALLJason Xu, Jonathan H Sussman, Austin Yang, et al.
Blood Cancer Discovery|April 14, 2026
3D chromosome remodeling in B-cell development and acute lymphoblastic leukemiaYohana E Ghebrechristos, Nikki A Evensen, Romane S Cathelin, et al.
Blood|March 25, 2020
Increased mTOR activation in idiopathic multicentric Castleman diseaseDaniel J Arenas, Katherine Floess, Dale Kobrin, et al.
Blood Cancer Discovery|May 28, 2025
Impact of Genetic Ancestry on Genomics and Survival Outcomes in T-cell Acute Lymphoblastic LeukemiaHaley Newman, Shawn H R Lee, Petri Pölönen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2019
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)Yael P Mossé, Elizabeth Fox, David T Teachey, et al.
Blood|February 6, 2014
The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trialMichael A Pulsipher, Bryan Langholz, Donna A Wall, et al.
Pageof 21